11.28
+0.22(+1.99%)
Currency In USD
Address
1560 Trapelo Road
Waltham, MA 02451
United States of America
Phone
781 786 8230
Website
Sector
Healthcare
Industry
Biotechnology
Employees
191
First IPO Date
September 17, 2020
| Name | Title | Pay | Year Born |
| Mr. John G. Cox M.B.A. | Chief Executive Officer, President & Director | 1.03M | 1963 |
| Dr. Oxana Beskrovnaya Ph.D. | Chief Scientific Officer | 719,521 | 1961 |
| Dr. Douglas Kerr M.B.A., M.D., Ph.D. | Chief Medical Officer | 745,640 | 1968 |
| Ms. Johanna Friedl-Naderer | Chief Commercial Officer | 748,769 | 1968 |
| Dr. Ashish Dugar M.B.A., Ph.D. | Chief Medical Affairs Officer | 0 | N/A |
| Ms. Lucia Celona | Chief Human Resource Officer | 0 | 1966 |
| Mr. Daniel Wilson | Senior Vice President & Head of Legal | 0 | 1972 |
| Mr. Vikram Ranade Ph.D. | Chief Business Officer | 0 | N/A |
| Ms. Debra Feldman | Chief Regulatory Affairs Officer | 0 | 1971 |
| Mr. Erick J. Lucera C.F.A., CPA | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer | 0 | 1968 |
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..